|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125373 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-26 11:22:57 |
|
注册时间: Date of Registration: |
2026-05-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
孤独症儿童经颅光刺激干预 |
|
Public title: |
Intervention of transcranial photobiomodulation for children with autism spectrum disorder |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
孤独症儿童的个体化多模 态神经调控技术 |
|
Scientific title: |
Individualized multimodal neuroregulation technology for children with autism spectrum disorder |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘楠 |
研究负责人: |
刘楠 |
|
Applicant: |
Nan Liu |
Study leader: |
Nan Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 574 8775 0587 |
研究负责人电话:
Study leader's |
+86 574 8775 0587 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
953092491@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
953092491@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省宁波市鄞州区桑田路502号 |
研究负责人通讯地址: |
浙江省宁波市鄞州区桑田路502号 |
|
Applicant address: |
502 Sangtian Road, Yinzhou District, Ningbo City, Zhejiang Province. |
Study leader's address: |
502 Sangtian Road, Yinzhou District, Ningbo City, Zhejiang Province. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁波市康复医院 |
||
|
Applicant's institution: |
Ningbo Rehabilitation Hospital |
||
|
研究负责人所在单位: |
宁波市康复医院 |
||
|
Affiliation of the Leader: |
Ningbo Rehabilitation Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
宁波市康复医院(2025) 年伦理审查(科研第034)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宁波市康复医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Ningbo Rehabilitation Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-05 00:00:00 | ||
|
伦理委员会联系人: |
崔杰 |
||
|
Contact Name of the ethic committee: |
Jie Cui |
||
|
伦理委员会联系地址: |
浙江省宁波市鄞州区桑田路502号 |
||
|
Contact Address of the ethic committee: |
502 Sangtian Road, Yinzhou District, Ningbo City, Zhejiang Province. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 574 8775 0587 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
宁波市康复医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ningbo Rehabilitation Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省宁波市鄞州区桑田路502号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
502 Sangtian Road, Yinzhou District, Ningbo City, Zhejiang Province. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
政府拨款 |
||||||||||||||||||||||
|
Source(s) of funding: |
government allocations |
||||||||||||||||||||||
|
研究疾病: |
孤独症谱系障碍 |
||||||||||||||||||||||
|
Target disease: |
Autism Spectrum Disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本项目针对 ASD 儿童的科学诊断和有效干预的迫切需求,着手解决 ASD儿童情绪加工的动态神经振荡与网络协同异常神经机制、可解释深度学习模型驱动的个体化异常模式挖掘、个体化多模态神经调控的潜在机制和有效性验证等关键科学问题,预期突破高安全性的经颅光调控-神经反馈训练(Transcranial Photobiomodulation-Neurofeedback,tPBM-NFB)多模态调控系统集成技术、ASD 儿童动态情绪诱发与数据融合分析技术、辅助识别模型及其可解释性分析技术以及多模态调控方案设计等关键技术,从而提升 ASD 儿童诊疗的精准性和安全性,降低家庭与社会负担,助力“健康中国”战略实施。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project addresses the urgent need for scientific diagnosis and effective intervention for children with ASD. It aims to solve key scientific issues such as the dynamic neural oscillations and network coordination abnormalities in the emotional processing of ASD children, the explainable deep learning model-driven individualized abnormal pattern mining, the potential mechanisms and effectiveness verification of individualized multimodal neural regulation, and so on. It is expected to break through key technologies such as the integrated multi-modal regulation system technology of transcranial photobiomodulation-neurofeedback training (Transcranial Photobiomodulation-Neurofeedback, tPBM-NFB), the multimodal emotional induction and data fusion analysis technology for ASD children, the auxiliary identification model and its explainability analysis technology, and the design of multimodal regulation schemes. This will enhance the accuracy and safety of the diagnosis and treatment of ASD children, reduce the burden on families and society, and contribute to the implementation of the "Healthy China" strategy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄3-12周岁,男女不限; 2.儿童监护人提供知情同意并在同意书上签字; 3.ASD儿童均由经验丰富的医生根据 DSM-V 标准诊断为孤独症。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age range: 3 - 12 years old, gender not restricted; 2. The guardian of the child must provide informed consent and sign the consent form; 3. All ASD children are diagnosed as autism by experienced doctors based on the DSM-V standards. |
||||||||||||||||||||||
|
排除标准: |
1.患儿伴有ADHD、RETT 综合征和发育迟缓等其他脑发育障碍疾病; 2.患儿具有严重的身体疾病,脑外伤史,癫痫史; 3.6周内接受过非侵入式刺激如tDCS,TMS等; 4.除常规行为训练外,服用过精神类疾病药物; 5.未签署知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The child has other brain development disorders such as ADHD, RETT syndrome and developmental delay; 2. The child has serious physical diseases, a history of brain trauma, and a history of epilepsy; 3. Received non-invasive stimulation such as tDCS and TMS within 6 weeks; 4. In addition to conventional behavioral training, has taken psychotropic drugs for mental disorders; 5. Has not signed the informed consent form. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-31 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2026-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用简单随机分组方法,将所有受试者按1:1比例随机分配至干预组与对照组,每组各30人。首先,为每位受试者分配唯一编号,并将所有受试者信息录入SPSS软件。随后,使用SPSS的随机数生成功能,为每位受试者随机分配一个0至1之间的数值,作为分组依据。通过对生成的随机数进行升序排列,打乱原始受试者编号的顺序。完成排序后,按照排序结果将前半部分的30名受试者分配至干预组,其余30名分配至对照组。最终形成两个受试者组别,用于干预实施与效果评估。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study employed a simple random grouping method, randomly allocating all the participants to the intervention group and the control group in a 1:1 ratio, with 30 participants in each group. Firstly, a unique number was assigned to each participant, and all the participant information was entered into the SPSS software. Subsequently, using the random number generation function of SPSS, a value between 0 and 1 was randomly assigned to each participant as the grouping basis. By sorting the generated random numbers in ascending order, the original sequence of participant numbers was disrupted. After the sorting was completed, the first half of the 30 participants were assigned to the intervention group, and the remaining 30 participants were assigned to the control group. Finally, two participant groups were formed for the implementation of the intervention and the evaluation of its effects. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对评估者、数据分析人员实施盲法。 |
|
Blinding: |
Implement blinding for the evaluators and data analysts |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在研究学术论文发表后6 个月内公开原始数据,向研究的项目联系人(康健楠教授,kangjiannan81@163.com)联系索取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publish the original data within 6 months after the publication of the research academic paper, contact the project contact person (Professor Kang Jiannan,kangjiannan81@163.com) for request. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由研究团队成员填写病例记录表,并将数据上传至电子采集和管理系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The research team members fill in the case record form and upload the data to the electronic collection and management system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |